-
Mashup Score: 0
November 9, 2022 — CinCor Pharma, Inc. announced the presentation today of Phase 2 data from its BrigHtn trial as part of the late-breaking science session at the 2022 American Heart Association (AHA) Scientific Sessions. Baxdrostat is a highly selective, once daily oral small molecule inhibitor of aldosterone synthase. “We were honored to present our Phase 2 BrigHtn data as part of a…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0
Original Article from The New England Journal of Medicine — Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
.#NEJM: Multicenter, Phase 2, placebo-controlled #RCT. Patients with treatment-resistant #hypertension who received #baxdrostat (selective #aldosterone synthase inhibitor) had dose-related reductions in blood pressure. #cortisol #HTN #CVD #NHLBI https://t.co/IOUAg29OeL https://t.co/Ep06rZS3Ti
-
-
Mashup Score: 0Dexamethasone a Safe Premedication Option for Patients With Primary Aldosterone Who Are Allergic to Iodine Contrast Media - 2 year(s) ago
Prednisone is the pretreatment standard, but can make AVS interpretation difficult
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
How does your center approach the issue, and how did that approach lead to this study? #Allergy #Aldosterone #Endocrinology #ESReadingRoom @TheEndoSociety Read more: https://t.co/tC3QjeOJrV https://t.co/C7od4pFprx
-
-
Mashup Score: 2Adrenal surgery for bilateral primary aldosteronism: an international retrospective cohort study - 2 year(s) ago
Primary aldosteronism is the most common form of endocrine hypertension. The condition is diagnosed in around 6% of all patients with endocrine hypertension1 and is associated with a particularly severe form of hypertension that is often resistant to standard treatment.2 Unilateral forms, mostly caused by an aldosterone-producing adenoma, represent around a third of cases and are treated by…
Categories: Endocrinology, Latest HeadlinesTweet-
Our findings challenge the current dogma of routine medical management of patients with bilateral excess of #aldosterone https://t.co/lDQScVrLJ6 primary #aldosteronism #FREE to read https://t.co/2ntgq6s35O
-
-
Mashup Score: 5Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms - 2 year(s) ago
Mineralocorticoid receptor (MR) activation is involved in propagating kidney injury, inflammation, and fibrosis and in the progression of chronic kidney disease (CKD). Multiple clinical studies have defined the efficacy of MR antagonism in attenuating progressive kidney disease, and the US Food and Drug Administration recently approved the nonsteroidal mineralocorticoid receptor antagonist (MRA)…
Categories: Cardiologists, Latest HeadlinesTweet-
#Aldosterone, #Mineralocorticoid Receptor Activation, and #CKD: A Review of Evolving Treatment Paradigms #MRAs #NephroTwitter #Nephrology #CardioTwitter #HeartFailure https://t.co/9CL7fsuSri @Nephro_Sparks @kidney_boy @AndrewJSauer @JavedButler1 @SJGreene_md @WilfriedMullens https://t.co/lyQXPsLsdg
-
-
Mashup Score: 2
This editorial refers to ‘Aldosterone in chronic kidney disease and renal outcomes’, by A. Verma et al., https://doi.org/10.1093/eurheartj/ehac352.
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
#Aldosterone excess and #cardiorenal risk: more common than appreciated Aldosterone effects on changes effecting CV and renal disease progression coupled with results of the #FIDELITY analysis https://t.co/9utoBJ12pp #HeartFailure @ESC_Journals @ShelleyZieroth @AndrewJSauer https://t.co/68MXoCpPNk
-
-
Mashup Score: 1Aldosterone in chronic kidney disease and renal outcomes - 2 year(s) ago
AbstractAims. Randomized controlled trials have demonstrated the efficacy of mineralocorticoid receptor (MR) antagonism in delaying chronic kidney disease (CKD)
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
#Aldosterone in CKD and renal outcomes These observational data suggest that pathogenic #aldosteronism may play a role in CKD progression #MRA therapy as a method to delay CKD progression in those without #DM ? https://t.co/eQsr7Np7Gn #EHJ #HeartFailure @ESC_Journals https://t.co/KW4FjhyLpC
-
-
Mashup Score: 7Aldosterone linked to increased risk of chronic kidney disease progression and end-stage kidney disease - 2 year(s) ago
A steroid hormone called aldosterone is linked to an increased risk of kidney failure in patients with chronic kidney disease (CKD), according to a study published in the European Heart Journal today. The risk of CKD worsening and developing into end-stage kidney disease was independent of whether or not patients had diabetes.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet-
#Aldosterone linked to increased risk of chronic #kidneydisease progression and end-stage kidney disease https://t.co/LDEPe1pxo1
-
-
Mashup Score: 0Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial | Oxford Academic - 2 year(s) ago
This PDF is available to Subscribers Only View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription. Close
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet-
The impact of Patiromer in patients with heart failure and reduced ejection fraction: #EHJ news from the DIAMOND trial! #Heart #failure #renin-angiotensin #aldosterone #inhibitors# hyperkalemia #patiromer #cardiotwitter #ehj @ESC_Journals @escardio https://t.co/RjW4qOaEOG https://t.co/UUUfIBOall
-
-
Mashup Score: 2Sex-Related Signaling of Aldosterone/Mineralocorticoid Receptor Pathway in Calcific Aortic Stenosis - 2 year(s) ago
Background: There are sex differences in the pathophysiology of aortic valve (AV) calcification in patients with aortic stenosis, although the molecular and cellular mechanisms have not been elucidat
Source: HypertensionCategories: Cardiology News and Journals, Latest HeadlinesTweet-
A new article reveals information about sex-dependent signalling and beneficial inhibition of the #Aldosterone #Mineralocorticoid receptor pathway in #AorticStenosis @rafasadaba @Navarrabiomed @salud_na https://t.co/1m9LCVgXwg https://t.co/syc0uw7mQL
-
@DAICeditor @cincorpharma #Aldosterone and #renin biomarker activity clinically demonstrate how #baxdrostat mechanistically achieves selective #bloodpressure lowering effects with no impact on #cortisol: https://t.co/M6DPvTsyAe #AHA22